3D Signatures (TSX-V:DXD) named Helen Stevenson to the board and Ian Smith, who is stepping down from the board, to the clinical and scientific advisory board (CSAB).
Ms. Stevenson is founder and CEO of Reformulary Group, which is focused on helping manage prescription drug costs for employer drug plans. She was formerly executive officer of Canada’s largest provincial drug program, the Ontario Public Drug Program by Order-In-Council, as well as assistant deputy minister at the Ontario Ministry of Health and Long-Term Care.
Dr. Smith, an original member of the 3DS board, is currently chairman of the Centre for Imaging Technology Commercialization. He is a former director general of the NRC Institute for Biological Sciences in Ottawa, and founder and director general of the Institute for Biodiagnostics in Winnipeg.
